NeuroMab™ Anti-IL10 BBB Shuttle Antibody(NRZP-1022-ZP2890)

Figure 1 provides a comparison of the antigen binding properties of humanized antibody variants with chimeric cB-N10 antibody using hIL-10 antigen ELISA.

Figure 2 presents the results of an assay of the binding properties of the three humanized variants hVH20/hVL7, hVH20/hVL8 and hVH26/hVL7 compared to chimeric B-N10 antibodies using purified antibody preparations.

Figure 3 shows the level of TNFalpha release in whole blood cultures of healthy volunteers after incubation with B-N10 compared to BT-063 (50 μg/ml).

Figure 4 shows the release levels of IL-6 from whole blood cultures of healthy volunteers after incubation with B-N10 compared to BT-063 (50 μg/ml).

Figure 5 shows the release levels of IL-1beta from whole blood cultures of healthy volunteers after incubation with B-N10 compared to BT-063 (50 μg/ml).

Figure 6 shows the levels of IFNγ released from whole blood cultures of healthy volunteers after incubation with B-N10 compared to BT-063 (50 μg/ml).

Figure 7 shows the mean cmax of cytokine concentrations in plasma following administration of BT-063 to healthy volunteers as a function of dose.

Figure 8 is a graph showing the mean concentration of IL-10 in plasma over time after administration of BT-063 in healthy volunteers.